SCHEMBL6758252

SCHEMBL6758252

CCCN(Cc1nc2ccccc2n1C)c1ccc2sc(C(=O)N3CCN(CC)CC3)cc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
HDAC6 Q9UBN7 3/20 0.45
HRH4 Q9H3N8 1/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
MEN1 O00255 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
HDAC1 Q13547 1/20 0.40
DRD2 P14416 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759291 0.94 HRH4 (0.49) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL6755014 0.87 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL6759310 0.85 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL6755065 0.84 KMT2A (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL6758117 0.81 HRH4 (0.48) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL6758072 0.81 NPC1 (0.48) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL6757422 0.81 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL6760871 0.79 HRH4 (0.48) ALDH1A1KDM4ELMNANPC1RAB9A
SCHEMBL6756425 0.77 HRH4 (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAHRH4
SCHEMBL6757428 0.76 HRH4 (0.46) ALDH1A1KDM4ELMNANPC1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040204417-A1 Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins PIERRE FABRE MEDICAMENT (FR) 2004-10-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204417-A1 Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins CBR1, CBR3, HCCS ALDH1A1 2558/4885KDM4E 2166/4885SMN1; SMN2 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.